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Abstract
The evolutionary events that cause colorectal adenomas (benign) to progress to carcinomas 
(malignant) remain largely undetermined. Using multi-region genome/exome sequencing of 24 
benign and malignant colorectal tumours, we probe the evolutionary fitness landscape occupied by 
these neoplasms. Unlike carcinomas, advanced adenomas frequently harbour sub-clonal driver 
mutations, which are considered to be functionally important in the carcinogenic process, that have 
not swept to fixation, and have relatively high genetic heterogeneity. Carcinomas are distinguished 
from adenomas by widespread aneusomies that are usually clonal and often accrue in a 
“punctuated” fashion. We conclude that adenomas evolve across an undulating fitness landscape, 
whereas carcinomas occupy a sharper fitness peak, probably owing to stabilising selection.
Introduction
The classical adenoma-carcinoma sequence of colorectal tumorigenesis1 postulates that a 
conventional colorectal adenoma (CRA) is initiated by “two hits” at APC2,3, and typically 
progresses to colorectal cancer (CRC) through a stepwise accumulation of driver mutations 
such as KRAS and TP53 and deletion of chromosome 18q4. The evolutionary dynamics 
presumed to underlie this process comprise a series of selective sweeps to (near) fixation, 
each triggered by an elevation in sub-clone fitness through the occurrence of a new, 
positively-selected driver mutation5. In this model, progression to an invasive lesion 
(carcinoma) is postulated to be prompted by the acquisition of a critical driver mutation 
burden, implying that adenomas and carcinomas should be distinguishable by specific driver 
mutations. CRCs can, however, develop without the full complement of driver mutations6,7, 
and some studies have suggested that sub-clonal evolution within established tumours is 
‘effectively neutral’8,9, questioning whether selective sweeps occur at all, especially in 
established CRCs.
As part of a comprehensive assessment of colorectal tumour evolution, here we have 
attempted to re-assess the classical model and outline the evolutionary ‘fitness landscape’ of 
CRAs and CRCs. The fitness landscape, a concept, first introduced by Sewall Wright in 
193210, is an abstraction to help visualise the relationship between genotypes and 
reproductive success (sub-clone fitness in this context). The X- and Y-axes can be thought of 
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as the genotype ‘space’ (simplified to 2 dimensions) that can be occupied by adenomas and 
carcinomas. The Z-axis or height is proportional to genotype fitness: peaks represent 
particularly fit genotypes, valleys less fit genotypes, and ridges/plateaux equally fit 
genotypes. Individuals sampled from a population are likely to occupy (local) fitness peaks, 
because less fit individuals have been removed by negative (purifying or stabilising) 
selection. Herein we search for the genotypes associated with the fitness peaks occupied by 
CRAs and CRCs and probe peak shapes by quantifying intra-tumour heterogeneity (ITH). 
Transitions around the landscape are measured using phylogenetic and molecular clock 
analyses. These data provide a comprehensive understanding of the evolutionary trajectories 
underpinning the development of CRAs and CRCs.
Results
To map the evolutionary landscape of CRAs and CRCs, we performed multi-region whole-
genome sequencing (WGS) or whole-exome sequencing (WES) on 2-16 regions (total 118) 
from 9 CRAs and 15 CRCs, each with constitutional DNA (Table S1 for sample details and 
S2 for sequencing statistics). Five CRCs, including four from Lynch syndrome patients, had 
microsatellite instability (MSI) owing to defective DNA mismatch repair, and these tumours 
were analysed as a distinct group unless otherwise stated. The remaining ten CRCs were 
microsatellite-stable (MSS) and of these, two were synchronous lesions from a single 
patient. Mutations in a subset of genes were validated using targeted molecular inversion 
probe sequencing (Online Methods).
Somatic single nucleotide alterations do not define CRC fitness peaks
We first assessed how somatic single nucleotide alterations (SNAs) defined the co-ordinates 
of CRAs and CRCs in the fitness landscape. CRAs tended to have only slightly fewer SNAs 
than MSS CRCs CRAs: median exonic burden=94, 95% range [51-146]; MSS CRCs: 
median=130, 95% range [98-171]; p=0.29 Wilcoxon test; Figure 1A, Table S2). After 
sequencing coverage normalisation, the mutational frequency in CRAs remained very 
similar to that of MSS CRCs (CRA; 4.1/Mb [3.3-4.9], MSS CRC; 4.2/Mb [2.9-6.4], p=0.9).
Next we compared the burden of driver mutations across CRAs and CRCs, and included 
SNAs and indels, and also cnLOH and monosomy (chromosome loss) events that are known 
to act as ‘second hits’ to the tumour suppressor genes APC and TP53, and also 18q allelic 
loss/imbalance (Figure 1C-D and Table S3). The burden of tier 1 mutations, which we 
defined as likely pathogenic changes in known CRC driver genes (see Online Methods, 
Table S4), was not significantly different in our cohort (CRAs: median=5 [2-9]; MSS CRCs: 
median=6 [2-8], p=0.9). We noted that the difference remained non-significant when 
comparing drivers across individual biopsies (p=0.19; Wilcoxon test). Individual tier 1 driver 
mutations were detected at similar frequencies across CRAs and CRCs, with the exception 
of TP53, which was more commonly mutated (possessing least one SNA, indel or copy 
change) in CRCs (Fisher test; p=0.005, see Figure 1D and Table S5). The frequency of tier 2 
driver mutations (uncertain pathogenicity changes in CRC or pan-cancer driver genes) was 
also not discernably different in CRAs and MSS CRCs (CRAs: median=3 [2-4]; MSS 
CRCs: median=3 [1-7]; p=0.8). Several tier 2 driver mutations were specific to CRAs or 
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CRCs, but most occurred infrequently; only KMT2C was notable, being mutated in 4 CRAs 
and no CRCs. The total driver mutation burdens (tier 1 and 2 combined; medians CRAs=7 
[2-12]; CRCs=8 [3-15]; p=0.6; Figure 1C, Tables S3, S4) were also similar. Furthermore, 
when using an alternative definition of driver genes (the top 15 genes mutated in MSS CRCs 
[excluding TTN], according to the TCGA publication7, Table S4b), the burdens remained 
not statistically different in CRAs and CRCs (CRAs: median=5 [2-7]; MSS CRCs: 
median=5.5 [2-9], p=0.7).
The power to detect differences in mutation burden between CRAs and CRCs was limited by 
sample size, such that differences in exonic mutation burden smaller than approximately 30 
mutations could not be detected with high power (see supplementary methods for post hoc 
power calculation). With this constraint in mind, SNA mutation burden (including tier 1 
driver mutations) did not distinguish the relative co-ordinates of CRAs and CRCs in the 
evolutionary landscape.
Intra-tumour heterogeneity and phylogenetic analyses suggest that CRCs occupy sharper 
fitness peaks than CRAs
To broadly assess the shape of the fitness peaks occupied by CRAs and MSS CRCs, we 
measured the degree of ITH in each tumour. Excluding tumours with only two regions 
sampled (see Online Methods), a median 56% [53-70%] of all CRA SNAs were “sub-
clonal” (variant not detected in all sampled regions). MSS CRCs had a significantly lower 
proportion of sub-clonal SNAs (45% [23-77%]; p=0.04; Figure 2 inset) than CRAs. The 
average pairwise genetic divergence between the regions of each tumour was then assessed 
following normalisation of sequencing coverage (Online Methods). CRAs showed 
significantly more divergence between biopsies than CRCs (CRA mean=2.0 versus 
CRC=1.7, divergent SNAs/Mb; p<2x10-16; Figure S1A), despite having the same average 
mutation burden. The measured values of ITH were unaffected by the number of biopsies 
available from each neoplasm (Figure S1B-C).
To further quantify ITH, we used SNAs to construct maximum parsimony phylogenetic trees 
(Figure 2). CRC topologies were often characterised by long trunks (variants ubiquitous 
across biopsies) with comparatively short branches and leaves (relatively few sub-clonal 
variants), thus appearing ‘palm tree-shaped’11. CRAs had proportionally shorter trunks, and 
thus longer branches/leaves than CRCs, albeit at borderline significance (average branch and 
leaf length as a proportion of the trunk: CRAs 82% versus MSS CRCs 50%; p=0.06; Figure 
2, Table S6). The difference remained when the MSI+ CRCs were included in the analysis 
(CRAs 82% versus all CRCs 45%; p=0.05). CRAs are thus more genetically diverse than 
CRCs.
To investigate whether individual CRAs and CRCs occupied single or multiple fitness peaks, 
we compared the lengths of the phylogenetic tree branches/leaves. Large variations in 
branch length indicate that mutations accrue faster in some tumour regions than others, 
which can potentially be caused by selection on a new fitness peak. Average intra-tumour 
variation in relative branch/leaf length was generally low and similar across CRAs and 
CRCs (mean standard deviation: CRA 0.14 [0.06-0.24] versus CRC 0.2 [0.06-0.47]; p=0.68; 
Figure 3, Table S6). Formal assessment of unbalanced tree topologies could only be 
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performed on one tumour (carcinoma 6) as high numbers of samples are needed for 
sufficient power12. Unbalanced trees occur when some ancestor clones produce more 
surviving lineages than another, another potential indicator of sub-clonal selection. We did 
not find any significant asymmetry in this single tumour analysis (Colless’ test, Yule model, 
p=0.3). Thus the available data were consistent with the idea that tumours occupied a single, 
potentially broad, fitness peak.
The SNA-based ITH and phylogenetic analyses suggested that CRAs were more 
heterogeneous than CRCs, consistent with the former occupying a broader fitness peak, 
under which several distinct genotype-phenotype combinations could co-exist. The lower 
ITH in CRCs could also, however, reflect a more recent selective sweep with a genetic 
bottleneck during the transition from an adenoma, and/or that CRCs were more spatially 
mixed than CRAs, causing variants at sub-clonal frequency in multiple samples to appear 
truncal. We therefore directly sought evidence of stronger selection in CRCs by examining 
the ratio of non-synonymous to synonymous mutations on tumour trunks and branches/
leaves. This showed a reduction in non-synonymous mutations on the branches/leaves of 
CRCs relative to their trunks (Wilcoxon sign rank test, p=0.01; Figure S2), but no such 
reduction for CRAs (p=0.9), possibly representing on-going positive subclonal selection in 
CRAs. On the reasonable assumption that positive selection acted on the phylogenetic trunk 
- the location of almost all tier 1 driver mutations – together these results indicate that 
subclonal selection is absent (neutral dynamics) or weak within the established carcinoma, 
with possible negative (stabilising) selection also at play.
Mutational processes are not detectably associated with fitness advantages
Mutation signatures were identified de novo using the EMu program13. We recovered 
ageing, MSI-associated and molecular clock signatures14 (our Signatures A, B and C 
respectively), as expected (Figure S3A). Our Signature D, which resembles COSMIC 
Signature 17 (unknown aetiology, high CTT>CGT frequency15) was present at appreciable 
levels within carcinomas 2, 7, 9P and 10, with its activity often differing between the trunks 
and branches/leaves of the same lesion (Figure S3B,C). We explored whether signature D 
had any effect on sub-clonal evolution in CRCs with WGS. It appeared to increase the 
mutation burden in two CRCs 2 and 9P, but had no discernible effect on their evolution 
(details in Figure S3D). Carcinoma 9D, the synchronous partner of carcinoma 9P, showed 
low signature 17 activity, despite being located only 10cm apart in the bowel. These cancers 
also had different driver mutations, confirming that they essentially behaved as independent 
neoplasms, with no detectable effect of any shared microenvironment on mutagenic 
processes (Figure S4).
Major driver mutations can be sub-clonal in CRAs, but are very rarely so in MSS CRCs
Tier 1 driver mutations (defined above) were typically, but not always, clonal in CRAs, 
whereas in MSS CRCs drivers were more commonly clonal. However, these distributions 
were not significantly different between tumour types (CRAs=39/49, 80% versus 
CRCs=49/55, 89%; p=0.3). The clonal distributions of tier 2 clonal driver mutations were 
however, different; CRAs had significantly less clonal drivers than MSS CRCs (CRAs=7/15, 
47% versus CRCs=21/26, 80%; Fisher’s exact test, p=0.03, Table S3). We noted that the 
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clonality of tier 1 driver mutations was the same when using the second definition of driver 
mutations based on the TCGA publication7 (37/43, 86% versus 45/53, 85%; Fisher’s exact 
test, p>0.9, see Online Methods). The findings are consistent with a scarcity of sub-clonal 
expansions after the most recent common ancestor (MRCA) in CRCs. This trend seems to 
be similar in CRAs, though CRAs do show some evidence of sub-clonal driver mutations.
We additionally noted, however, that the most frequently mutated CRC driver genes, apart 
from the probable tumour-initiating mutations in APC, were sub-clonal in at least one CRA. 
Notably in adenoma 2, KRAS Q61H and an ARID2 frameshift mutation were present in one 
region, which was separate from the three regions of this tumour that contained a TP53 
E219X mutation. Adenoma 3 had a PIK3CA E545K mutation in two tumour regions, GNAS 
R201H in another, and an AKAP9 frameshift in another. SMAD4 R496H in adenoma 4 was 
also present in a single region. There was no evidence from the phylogenetic analysis that 
these proven driver mutations were associated with differential sub-clonal expansion, 
suggesting that their selective benefits were relatively modest (Figure 2). NRAS G60V and 
PIK3CA H1047R were present in both regions of adenomas 7 and 8 respectively, but were 
putatively sub-clonal since their corrected allele frequencies were significantly lower 
(p<0.05) than those of other driver mutations, suggesting that biopsies crossed sub-clonal 
boundaries. By contrast, only one sub-clonal mutation with high-confidence pathogenicity 
(CHD1 R619X in carcinoma 1) was found in the MSS carcinomas. There was no evidence 
for parallel evolution of sub-clones based on recurrent known or novel drivers (details not 
shown).
We next we wished to relate the heterogeneity of mutational burdens to fundamental 
molecular processes. Immunohistochemistry for Ki-67 (proliferation) and β-catenin 
(activated Wnt-signalling; Figure S5; Online Methods) showed positive cell fractions of 53% 
[2-80%] and 82% [3-97%] respectively, with considerable variability between and within 
CRCs (Table S7). Neither Ki67 nor β-catenin expression was associated with regional SNA 
burden or ploidy (SNA burden, R2=0.2, p=0.2, ploidy, R2=0.9, p=0.08; Figure S5).
Genetic and spatial relationships between CRC sub-clones
In all CRCs, physical and phylogenetic distances between biopsies were strongly correlated 
(R2=0.81-0.93, p<10-4 for all carcinomas measured; Figure 4). The invasive edge of CRCs 
and central regions had similar mutational burdens (exonic SNAs, edge versus central; 
p=0.76). We looked further for sub-clonal mixing within the sampled regions of the MSS 
CRCs with WGS data by clustering of SNA cancer cell fractions across related samples, 
using a Dirichlet process-based model (Figure S6). Only 10% of biopsy samples showed 
evidence of ≥1 sub-clonal population. Whilst we do not exclude a degree of sub-clonal 
intermingling, these results suggest that, given the depth of our sequencing data, sub-clonal 
expansions broadly occurred in a spatially contiguous, uniform and discrete fashion.
Copy number changes differ between CRAs and CRCs
We next assessed whether somatic copy number alterations (CNAs) might define the fitness 
peaks occupied by CRAs and MSS CRCs. Every region of every tumour carried at least one 
CNA, including cnLOH (see Online Methods). In a combined analysis of all regions from 
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each tumour, as expected, adenomas had fewer CNAs (number of discrete CNA segments 
>1Mb) than carcinomas16,17 (CRAs median=13 [7-11] versus CRCs median=40 [15-42], 
p=0.003; Figure 1B). Correspondingly, the overall average proportion of the genome 
disrupted by CNAs (copy number ≠ 2, allelic ratio ≠ 1) was higher in CRCs (CRCs, 72% 
versus CRAs, 40%; p=0.05; Figure 3). These data show that despite carrying similar SNA 
burdens, CRCs display higher CNA levels than CRAs.
Driver CNAs are currently hard to identify with certainty in cancer18. In colorectal tumours, 
losses (deletions or cnLOH) on chromosomes 5q, 17p and 18q are often thought to be 
second hits involving tumour suppressors APC, TP53 and SMAD4 respectively (although 
18q loss is more common than SMAD4 mutation). The status of other recurrent changes – 
such as 1q gain, 7 gain, 8p deletion, 13q gain and 20 gain – as drivers or passengers is less 
clear. Many recurrent, and hence potential driver7, CNAs were present at significantly 
higher frequencies in CRCs compared to CRAs (Figure 3). Notably, 17p loss occurred in 
9/10 MSS CRCs, but only 2/9 CRAs (Fisher’s exact test, p=0.005), paralleling the TP53 
SNA data. By comparison, loss at the APC locus (8/10 CRCs versus 5/9 CRAs; p=0.35) and 
the SMAD4 locus (7/10 CRCs versus 4/9 CRAs; p=0.37; Figure 2) occurred at similar 
frequencies in both lesion types.
Every tumour had at least 2 clearly sub-clonal CNAs (non-ubiquitous, present versus absent 
changes; Figure 3A) and no chromosome aberration was exclusively ubiquitous or sub-
clonal across the tumours. Overall, 75% and 48% of gains were sub-clonal in CRAs and 
CRCs respectively (p=0.002), compared with 57% and 27% of losses/cnLOH (p=0.007; 
Figure S7). Thus, a greater proportion of CNAs were sub-clonal in CRAs than in CRCs.
We compared the size distribution of large (>1Mb) CNAs in early (truncal) versus late (sub-
clonal) tumour evolution. In CRCs, sub-clonal CNAs were smaller than ubiquitous CNAs 
(p<0.001 ; Figure S3C), but this difference was not present in CRAs (p=0.45). The lower 
frequency of large CNAs later in evolutionary time in CRCs suggests that the cancers have 
obtained a near-optimal level of aneuploidy, with further large-scale CNAs subjected to 
negative/stabilising selection. In adenomas, since the overall CNA burden is lower, new 
large CNAs may still be tolerated.
MSS CRC evolution can involve either “punctuated” or more gradual CNA acquisition
Since CNAs were the principal genetic feature distinguishing CRAs and CRCs, we 
investigated their role in the transition between the benign and malignant fitness peaks. 
Utilising a similar strategy to Durink19 and Newman20 (details in Online Methods), we 
used the SNAs within informative chromosomal segments (copy number gains and cnLOH) 
as a molecular clock to time the occurrence of that CNA. SNAs present on a chromosome 
prior to gain, cnLOH or amplification increase in frequency (VAF) following the copy 
number change, whereas SNAs that accrue after the gain remain at their original, lower VAF. 
The ratio of higher to lower VAF SNAs therefore estimates the time of CNA occurrence.
Sufficient SNAs for molecular clock analysis were only present in WGS data. Of the five 
MSS CRCs analysed by WGS, carcinomas 3, 9P and 10 showed a clustering of CNA 
timings shortly before the MRCA (Kolmogorov-Smirnov test against a uniform distribution 
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of CNA timings, p<0.02 for all, Figure 5). A similar, borderline significant CNA cluster 
occurred in carcinoma 9D. Carcinoma 5 showed a more gradual accumulation of CNAs.
Since the timing method demonstrated a form of “punctuated” CNA evolution (rejection of 
null hypothesis of uniform accumulation), but did not distinguish between multiple gains of 
individual chromosomes and genome doubling followed by chromosomal gain or loss, we 
searched heuristically for evidence of genome doubling using a score based on the number 
of chromosome centromeres present at copy number 4 or above, with extra weight for allelic 
balance (Figure S8). Based on this measure, all of the CRCs with significantly or borderline 
significantly clustered CNA timings (n=4) were genome-doubled on this measure, as was the 
untimed carcinoma 8. The CNAs in these tumours are typically trisomies, judged to have 
arisen by chromosome (arm) loss subsequent to allele-balanced genome doubling. The other 
tumours (including carcinomas 1, 2, 4, 5, 6, 7) were scored as non-genome-doubled. Sub-
clonal genome doubling was present in one CRA (adenoma 2). This tumour carried a TP53 
mutation in its genome-doubled regions, and overall TP53 mutations (SNAs and/or CNAs) 
were associated with genome-doubling in MSS CRCs (Fisher’s Exact Test p=0.018). In 
addition, genome-doubled cancer regions had higher Ki67 expression (see above; p=0.04; 
Figure S5), hinting at the existence of a selective benefit of doubling.
The evolutionary landscape of microsatellite-unstable CRCs
The overall SNA burden of the 5 MSI+ CRCs was, as expected, far higher than in MSS 
CRCs (Figure S9A). More pointedly, the number of tier 1 CRC driver mutations was also 
higher (median=12 [4-14]) than in MSS CRCs, median=3, p=0.042, Figure S9B), whilst 
CNA burden was lower (Figure S9C). Of note, in MSI+ CRCs, the great majority of driver 
SNAs were truncal, the number of sub-clonal tier 1 drivers was only a little greater 
(median=1 [0-7]) than in MSS CRCs, and the proportion of all sub-clonal SNAs was not 
significantly increased (median MSI+ CRCs 34% versus MSS CRCs 42%; p=0.13; Figure 
S9D). In phylogenetic analysis, neither the average branch/leaf length as a proportion of the 
trunk nor its variability differed significantly between MSI+ and MSS CRCs (Figure S9E). 
Our signature B (COSMIC signature 6) predominated in MSI+ CRCs, especially on the 
branches/leaves, but the other COSMIC MSI-associated signatures14 were not detected. 
Overall, the data suggest that MSI+ CRCs evolve in a similar way to MSS CRCs, albeit with 
some limited evidence of sub-clonal selection.
Discussion
Here we have contrasted the patterns of evolution in colorectal carcinomas and their 
classical adenomatous precursor lesion, and our data begin to reveal the shape of the fitness 
landscape over which CRCs grow. CRAs tend to evolve through acquisition of major driver 
mutations in genes such as APC, KRAS, TP53 and via 18q loss as per the Kinzler and 
Vogelstein model4. More recently discovered cancer driver mutations are also present in 
many adenomas (Table S3 & S4). In fact, CRAs can harbour mutations in any of the major 
CRC driver genes, but those mutations do not necessarily occur in a stereotypic order. Driver 
mutation acquisition also does not necessarily cause selective sweeps (leading to ‘stepwise’ 
evolution of the tumour cell population), since sub-clones with additional major driver 
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mutations may not displace sub-clones lacking those mutations, but instead may co-exist in 
spatially discrete areas. It follows that many driver mutations probably confer a relatively 
small selective advantage. This is reflected in several observations in CRAs, including a 
relatively high level of genetic diversity (both SNAs and CNAs), variation in the major 
driver mutation complement in different regions of individual tumours, and phylogenetic 
trees with relatively long branches/leaves. It is even possible that SNA accumulation is not 
an essential feature of tumorigenesis prior to malignancy, and we speculate that carcinomas 
need not arise from the sub-clone with the greatest number of driver mutations, thus 
explaining why some CRCs have a very small driver mutation complement7.
MSS CRCs have longer phylogenetic tree trunks than branches/leaves as compared to 
CRAs. These findings may reflect the influence of several factors, including not only 
selective constraints, but also time from the MRCA after an additional selective sweep, 
ploidy, sample purity and genomic instability. Overall, the lack of sub-clonal driver SNAs 
and reduction in non-synonymous SNAs on the branches and leaves of CRCs suggest that 
there is not strong positive sub-clonal selection for SNAs after the MRCA. CRAs on the 
other hand do show subclonal drivers and relatively high ITH together providing evidence of 
(perhaps relatively weak) subclonal selection.
Although present in CRAs, large CNAs and genome doubling are much more common in 
CRCs. CNAs on CRC tree branches/leaves are smaller than those on trunks. Whilst negative 
or stabilising selection remains difficult to measure, this is consistent with the relatively low 
genetic diversity in CRCs, based on SNAs and large CNAs. For most MSS CRCs, a near-
triploid karyotype seems optimal, either through genome doubling followed by loss of some 
chromosomes, or through a gain of chromosomes that mostly occurs within a putatively 
short time window between malignant progression and the MRCA. In each case, one or 
more selective sweeps seem to occur, rendering the driver SNAs and most CNAs clonal. We 
do not exclude additional positive selection for specific sub-clonal CNAs in CRCs, but this 
remains unproven and indeed our data showed no evidence of sub-clonal selection. Although 
every CRC had at least one sub-clonal CNA, we found no evidence of parallel CNA 
evolution.
In all our MSI+ cases, defective MMR and most major driver mutations arose on the 
phylogenetic trunk, and the relative branch/leaf length was similar to that of MSS CRCs. 
Although the sporadic MSI+ cancer had a low driver mutation burden, as expected if driven 
in part by a methylator phenotype21, its evolution was otherwise similar to the Lynch 
syndrome CRCs. We speculate that MSI+ CRCs experience either multiple selective sweeps 
driven by individual SNAs, or, more intriguingly, by co-occurring or epistatically acting 
non-canonical driver SNAs (such as CTNNB1, SOX9, NF1 and CASP8).
A small number of ITH studies have been undertaken previously in CRC. Kim et al22 and 
Uchi et al23 performed multi-region WES of 5 primary and metastatic CRCs and 9 CRCs 
respectively, and Suzuki et al24 performed deep targeted sequencing of 799 genes in four 
CRCs. Similar to our study, these studies reported that major driver mutations, affecting 
APC, KRAS and TP53, were truncal, with the exception of PIK3CA. Uchi et al23 also 
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reported that large copy gains were common on the trunk of the evolutionary tree, with focal 
deletions on branches.
Fewer studies of CRA evolution exist. Kim et al25 used WES to compare malignant and 
benign regions of 4 mixed cancer-in-adenoma polyps. They reported similar SNA burdens in 
cancer and adenoma regions, and thus suggested that the regions evolved in parallel, rather 
than the carcinoma progressing from a late adenoma. We note, however, that it is extremely 
hard to distinguish benign and malignant components of these lesions, since malignancy is 
defined not by cytology, but by invasion and hence the location of tumour cells. The 
different neoplastic components of such polyps may therefore, in reality, both be 
‘cancerous’. For these reasons, in this study, we based our comparison between advanced 
CRAs and CRCs that were distinct lesions.
Previous work from our group10 examined single glands from 11 CRCs and 4 CRAs for 
CNAs, and for Ampliseq panels of SNAs that had been derived from bulk tumour WES. 
Although that manuscript and our present study had very different focuses, the findings are 
consistent. For example, one feature of the “Big Bang” model of sub-clonal intermixing 
expounded in the previous study is that after the MRCA, CRC sub-clones radiate outwards 
without notable differential sub-clonal expansion or selection of further advantageous 
variants; our present study is broadly consistent with those data. There are also, however, 
some differences between the studies that allow refinement of the “Big Bang” model. For 
example, our current study, which benefits from the significantly increased genomic 
resolution of WGS/WES, emphasises that large sub-clones after the MRCA remain spatially 
restricted in CRCs and consequently that the previously observed, widespread clonal 
‘intermixing’ in some CRCs10 may reflect the shape, size, and boundary location of discrete 
sub-clones as well as outwards radiation of low frequency clones. Furthermore, whilst the 
“Big Bang” was broadly consistent with ITH measured in CRAs, our present study finds that 
sub-clonal driver mutations in the absence of selective sweeps occur commonly in these 
tumours.
In a study analogous to ours, Stachler et al26 exome-sequenced 5-11 samples of oesophageal 
carcinoma and its precursor, Barrett’s oesophagus (BE) from 5 patients. Comparing the two 
studies reveals both similarities and differences. BE is not a discrete tumour and is generally 
a highly polyclonal lesion, reflected in multiple “initiating” deletion mutations in CDKN2A 
and a series of clonal expansions without selective sweeps. By comparison, CRAs are 
discrete and probably have monoclonal origins usually caused by bi-allelic APC mutation, 
followed either by selective sweeps, or by polyclonal expansions reminiscent of BE. We note 
that in both BE27,28 and CRA, data are consistent with malignant progression sometimes 
occurring from a sub-clone that does not have the largest driver mutation burden.
In summary, we have used measurements of intra-tumour heterogeneity to reveal the 
evolutionary trajectories of colorectal tumour cell populations across what appears to be a 
rather flat fitness landscape for adenomas, with a higher, sharper peak occupied by cancers. 
Our data refine the Fearon and Vogelstein model4 of CRC progression by showing that 
driver mutations do not necessarily lead to hard selective sweeps and that progression to 
CRC can involve punctuated evolution.
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Methods
Sample acquisition and processing
Oxfordshire Research Ethics Committee B gave permission for the study (protocol 05/
Q1605/66), and all samples were collected with informed patient consent, that was obtained 
by the local clinicians prior to tissue collection. Fresh-frozen biopsies from 24 colorectal 
adenomas or carcinomas were obtained from the John Radcliffe Hospital, Oxford or from 
University Hospital, Basel. In the case of CRAs, the biopsies were obtained from endoscopic 
resections, whereas the CRC biopsies were obtained from surgical resections. Any residual 
bulk cancer surplus to diagnostic requirements was also acquired. Paired normal biopsies 
were also taken from regions clearly separate from the tumour.
Library preparation and sequencing
DNA was extracted from tumour regions and morphologically normal tissue using the 
Qiagen DNeasy® kit. The sequencing library preparations were performed using either the 
NEBNext® DNA kit or in the case of exome sequencing the Illumina TruSeq® exome kit. 
Sequencing of these biopsies was carried out using standard protocols on the Illumina HiSeq 
2000 by the Genomics Core at the Wellcome Trust Centre for Human Genetics, Oxford. The 
FastQC program29 was used to assess raw sequencing quality and coverage and depth were 
assessed using the GATK package (specifically the DepthOfCoverage module)30.
Pre-processing and nucleotide variant calling
Reads in FastQ format were aligned to version 19 of the human genome reference using 
BWA version 0.7.531. The Picard package32 was used to identify duplicate reads and the 
Samtools package33 was used to count the number of reads in the binary alignment map 
(.bam) files. Single nucleotide variant (SNA) calling was performed using the Platypus 
tool34. Variant call format (.vcf) files were annotated with AnnoVar35 and converted to tab-
delimited file format using snpSift36. SNAs were categorised as somatic if they were present 
in at least one tumour sample and either the normal sample had <40X coverage and zero 
mutant reads or ≥40X depth and ≤1 mutant read. To obtain high confidence and consistent 
variants for phylogenetic analysis, only variants called with depths consistently ≥10X and 
allele frequency ≥1% in one or more regions were retained.
Calling small insertions and deletions
Indel calling remains problematic and highly inaccurate37. For this reason we focussed 
mainly on potential driver events. We identified a set of reliable indels by performing a first 
pass using the Scalpel tool38 then verifying the presence in the Platypus call sets and also by 
visual inspection using the IGV browser39. On visual inspection, we found that many 
ubiquitous indels were actually called incompletely across the biopsy sets by Platypus and 
sometimes missed all together by Scalpel, highlighting the inconsistency of the currently 
available tools.
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Driver mutation identification
We used two classifications of driver genes (Table S3). First, we identified CRC drivers 
using the IntOGen database 2016.5 (https://www.intogen.org/). Driver mutations were then 
classified using a two-tier system. Tier 1 driver mutations were considered to be very likely 
involved in colorectal carcinogenesis and included canonical mutations such as most 
protein-truncating APC SNAs, BRAF V600E and KRAS codon 12, 13, 61, 117 and 146 
changes. For non-canonical mutations, tier 1 status was assigned to protein-truncating 
mutations in tumour suppressor genes or recurrently occurring mutations in CRCs in the 
COSMIC database (http://cancer.sanger.ac.uk/cosmic). Tier 2 mutations, considered to be of 
lower confidence as drivers, comprised all other coding or splice site changes in the same set 
of genes. These genes are defined in Table S3a. Second, we used a more restrictive 
definition of the top 5% significantly mutated genes in the TCGA publication exclusively 
(non-MSI+ carinomas). These genes are defined in Table S3b.
Coverage normalisation
We normalised for differences in sequencing coverage to avoid bias in mutation calling and 
intra-tumour heterogeneity measurements due to unequal coverage between samples. To do 
this, we identified a subset of 110,533 exonic regions consistently sequenced at ≥10X in all 
biopsies across all tumours. To normalise coverage between samples, we individually sub-
sampled each .bam file such that each contained a roughly equal number of reads. This 
equated to around 17,000,000 reads per biopsy, covering in total 25Mb of exonic regions.
We then generated 100 sets of ‘mini-bams’ (one bam from each sample) where each bam 
contained the same 10,000 regions randomly selected regions from the original 110,533 
well-covered regions. For each set of mini-bams we repeated the joint Platypus calling 
procedure (as per the above). The mutation frequency was calculated by simply taking the 
resulting number of variants and the total length of the 10,000 regions in each iteration.
Deep sequencing
In order to validate the exome and genome sequencing, and to search for additional low 
allele frequency somatic mutations, we sequenced a panel of 50 CRC driver genes in 
selected tumour regions. These genes encompassed all well established driver events 
including the top 15 genes from the IntOGen list (see Table S3) and included both tier 1 and 
2 driver mutations. Coding regions were captured using molecular inversion probes (MiPs) 
and sequenced using the Illumina NextSeq. Molecule tagging was used to ensure that reads 
were derived from unique tumour DNA molecules. Further details of the gene panel and the 
sequencing protocol are available on request.
All of the subset of 44 driver mutations identified by WES/WGS from three carcinomas and 
five adenomas were validated. We also were able to identified two additional ubiquitous 
APC mutations that had not been called in the WGS/WES data.
CNA calling
We used CloneHD40 to call absolute copy number and LOH profiles for each sample. We 
first collected raw read depth data across the genomes using Samtools. For WGS samples, 
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we used 1kb non-overlapping windows (excluding difficult regions such as centromeric). For 
WES samples, bed files corresponding to the exome capture kit were used and the data were 
further placed onto 20kb bins. For each set we utilised the corresponding normal sample to 
identify outlier bins, which we removed. Furthermore, variant call files for each sample set 
were used to identify germline heterogeneous loci to collect B-allele data, informative for 
LOH and/or unbalanced aberrations in the tumour samples.
We then ran filterHD (part of the CloneHD tool) to identify changes in the read depth and B-
allele tracks that go beyond the noise resulting from finite sequencing depth for each set40. 
Such “jump” locations were used as input for cloneHD copy number calling for the tumour 
samples. For WES samples we also used the corresponding normal samples to correct for 
platform related bias in the read depth tracks. The bias correction is important for WES 
samples and not using it would result in a large number of loci with high jump probability, 
i.e., over-segmentation (see discussion about bias correction40).
We validated the general patterns of large CNA to calls from SNP arrays (Illumina Global 
Screening Array) using the OncoSNP program on the majority of tumours. Overall, 93% of 
the larger CNAs were in congruence.
For this analysis, we did not report structural variants or chromosomal hypermutation events 
such as chromothripsis and chromoplexy.
Exclusion of tumours from analysis of heterogeneity
The ability to accurately measure ITH depends on the number of biopsies available from the 
tumour41. We assessed the relationship between biopsy number and genetic divergence and 
found no correlation (Fig S1B). A subsampling bootstrap analysis of three neoplasms each 
with a high number of biopsies showed that at least four biopsies per neoplasm provided a 
suitably accurate measurement of ITH (Fig S1C); hence neoplasms with less than four 
biopsies available were excluded from ITH analysis.
Analysis on sub-clonal populations
Since larger sub-clones might disturb the overall phylogenetic analysis, we investigated the 
existence of such in the samples with whole genome sequencing using the Battenberg 
algorithm42. Briefly, the algorithm phases heterozygous SNPs with use of the 1000 
genomes genotypes as a reference panel. The resulting haplotypes are corrected for 
occasional errors in phasing in regions with low linkage disequilibrium. After segmentation 
of the resulting b-allele frequency (BAF) values, t-tests are performed on the BAFs of each 
copy number segment to identify whether they correspond to the value resulting from a fully 
clonal copy number change. If not, the copy number segment is represented as a mixture of 
2 different copy number states, with the fraction of cells bearing each copy number state 
estimated from the average BAF of the heterozygous SNPs in that segment.
Clusters of subclonal substitutions were identified in whole genome sequencing data using a 
Bayesian Dirichlet process (DP) in n dimensions, where n is the number of related samples 
as previously described43. For each mutation, the allele frequency was converted to a cancer 
cell fraction (CCF) prior to clustering, allowing for purity and copy number estimates 
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obtained from the Battenberg algorithm, as described previously43. Clusters were identified 
as local peaks in the posterior mutation density obtained from the DP. For each cluster, a 
region representing a ‘basin of attraction’ was defined by a set of planes running through the 
point of minimum density between each pair of cluster positions. Mutations were assigned 
to the cluster in whose basin of attraction they were most likely to fall, using posterior 
probabilities from the DP.
We investigated the geographical spread of subclones by analysing the presence of each 
subclone across samples from each patient. Subclones may be: clonal (defined as CCF ≥ 0.9) 
in all samples; clonal in some samples and absent (defined as CCF ≤ 0.1) from others; 
present subclonally in a single sample; present in multiple samples and subclonal in at least 
one. The first three categories represent clones/subclones that are in defined geographical 
regions of various sizes, whereas the last category represents subclones that are more 
diffuse, indicative of subclone mixing across regions covering multiple biopsies. The 
percentage of mutations in this last category was low (median 12%, range 5-26%), 
indicating that where subclones were present they were generally in defined geographical 
regions.
Phylogenetic analysis
We built phylogenetic trees from the SNAs sets for each tumour using PAUP* software. We 
first converted each variant set into a binary matrix, where the rows related to a particular 
biopsy or the normal sample and the columns related to a specific variant. The binary 
encoding (0/1) designated absence or presence of a variant. A nexus file was used to specify 
the parsimony parameters needed for the tree construction along with the variant matrix. The 
following functions and parameters were used: (i) the outgroup function was used to root all 
resulting trees to the normal sample - effectively a column on the mutation matrix containing 
only zeros; (ii) the hsearch function was used to perform a heuristic search of 10,000,000 
trees from the given tree space, with 1000 of the shortest trees output for the main analysis; 
(iii) the bootstrap function was used to perform a sub-sampling procedure 10,000 times that 
involved randomly selecting a set of mutations from the binary matrix (with replacement), 
with the proportion of each branch instance was reported in a log file; and (iv) the alltrees 
function was used in the cases where less than 10 biopsies were present. This made it 
possible to perform an extended 'brute-force' run to acquire the definitely shortest tree(s) 
from the total search space, at the expense of computational time. The resulting .tre files 
were visualised and converted to .pdf format using FigTree software44. The homoplasy 
indexes for the most parsimonious tree in a given set was automatically calculated and 
output to the PAUP* log file.
To obtain the shortest and thus most parsimonious tree, an Rscript using the ape package45 
was used to input the .tre file. In all cases expect carcinoma 6 only one tree was the shortest. 
In the case of carcinoma 6 the 8 shortest trees were visually compared revealing that a 
specific clade was unresolved across these trees though the main topology was the same. For 
this case we build a consensus tree using the ape package, consensus function.
We also tested for phylogenetic consistency across the variant types. We produced subsets of 
the SNAs using only non-synonymous or synonymous mutations or if the whole genome 
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was available, the exome and then compared the resulting phylogenies with the original total 
data trees. Comparisons were performed in three ways: (i) topology structure, where 
identical topology matches were noted; (ii) the number of consistent terminal clades 
represented across each tree; and (iii) statistical comparison of tree topologies using the 
Penny and Hendy (P&H) symmetrical distance method. The P&H method was implemented 
using an R script and the apTreeshape package46. To obtain a p-value for the P&H index we 
build a distribution of random trees of the same length and number of taxa for a given set, 
thus enabling a probability to be determined for obtaining a given P&H index.
To perform tree balance analysis (which was only appropriate for carcinoma 6 that 
possessed > 15 samples), we used the Colless’s test function as implemented in the R 
apTreeShape package. We tested the topology of carcinoma 6 against a balanced ‘Yule’ tree, 
hence the p-value represents the likelihood of imbalance given this branching process.
Diversity analysis: adenoma versus cancer
To compare the SNA diversity of adenomas and carcinomas, we performed two main 
analyses. Firstly, we wanted to compare the proportion of truncal SNAs from the total SNAs 
called in adenomas and carcinomas, but since certain tumours had many more biopsies, we 
performed a biopsy-wise down-sampling procedure. Here, in tumours with more than four 
biopsies (this was considered a reasonable minimum) we randomly selected various four-
biopsy combinations and calculated the proportion of variants classified as trunk, branch and 
leaf. The distributions of these proportions was then plotted with the quartiles for the four-
biopsy samples.
Second, the downsampled call sets were used to assess the SNA diversity by measuring the 
SNA divergence of a pair of randomly selected biopsies from a given tumour. The diverging 
(non-shared) somatic variants were given as a number per Mb of the genome across the 100 
down-sampled iterations.
Mutational signatures with EMu
For each tumour set, we classified all SNAs based on their flanking trinucleotide sequence 
context47 and whether they fell onto the trunk (shared) or branches (including trunk and 
leaves) of the phylogenetic tree. Inference of mutational processes and their activities was 
then determined using the EMu algorithm48. Through this analysis we identified 4 
signatures (Signatures A, B, C and D). The resemblance to the COSMIC signatures was 
determined by comparing 96-channel mutation frequencies and by visual inspection.
Comparison of spatial and genetic distances
To obtain estimates of the physical distances between each biopsy from any tumour, we 
produced normalised measurements of the number of pixels on a straight-line drawn 
between the centre points of the biopsy locations. The photographs of the tumour and biopsy 
locations were used as reference. We then used the ape R package to obtain the inter-taxa 
distances for each of the phylogenetic trees and performed a linear regression of the physical 
on the phylogenetic distance for each tumour.
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Digital Pathology
Patient material was fixed in 10% buffered formalin and paraffin-embedded. Tumour blocks 
were sectioned at 4 μm. Ki67 and β-catenin proteins were analysed by 
immunohistochemistry using a Leica autostainer with haematoxylin counterstaining 
according to standard protocols (ki-67 antibody, DAKO MIB-1 cat no M7240, 1:150; β-
catenin antibody, BD biosciences cat no 610154, 1:50; DAB chromogen). All slides were 
scanned at 200x magnification on a 3D Histech Pannoramic Scanner and stored in MIRAX 
(.mrxs) format.
Digital image analysis was performed by a board-certified pathologist (VHK) using the 
HALO™ image analysis software, v.2.0.1145.19 (Indica Labs, Corrales, NM 87048, USA). 
Briefly, invasive cancer regions were identified on each scanned tissue section and manually 
annotated. Normal mucosa and regions of necrosis were excluded. Next, the HALO ™ 
classifier machine learning algorithm was trained to categorize tumour tissue, stroma and 
background regions for each stain. The goodness of classification was visually controlled on 
all cases. Marker-positive cancer cells were identified using the cytonuclear algorithm. 
Cellular recognition was trained and optimized on invasive cancer tissue. Colour 
segmentation was performed. The H&E nuclear stain was set as R=0.644, G=0.716, 
B=0.267, and the DAB positive stain as R=0.268, G=0.570, B=0.776. Algorithm settings are 
provided in Table S9. ki-67 and β-catenin stains were calibrated using normal, non-
proliferative mucosal cells outside of the crypt bases. The total counts and percentage of 
marker-positive cells in the tumour cell compartment were recorded.
General statistical analyses
All analyses were performed in R or STATA. Unless otherwise stated, all statistical 
comparisons of two distributions used the Wilcoxon test (Wilcox.test function in R). Unless 
otherwise stated, 95% confidence intervals of medians were determined using a 
bootstrapping analysis of the median values (1000 repeats of 20 samples [10 adenoma, 10 
carcinoma] with replacement). Data in contingency tables were analysed using Fisher’s 
exact test. Researchers were not blinded to sample type.
Power calculation for detecting a difference in mutation burden
We calculated the power to detect a difference in the mutation burden of 9 adenomas versus 
10 carcinomas. In accordance with the measured burdens, we assumed 90 mutations per 
adenoma (std. dev. 35 mutations) and considered the power of a t-test to detect a difference 
between the carcinomas with a variety of higher burdens, requiring a (one tailed) 
significance level of p<0.05. Standard formulae were used to calculate power. Our data had 
very good power to detect a 50% increase in burden in carcinomas and good/fair power to 
detect a 33% increase (Figure S10).
CNA timing model
Full details of the model are presented as a Supplementary Note. Matlab code to calculate 
the CNA timing is available from the GitHub project page: https://github.com/daniel-temko/
CNVTiming.
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We modelled the last common ancestor of WGS tumour samples by obtaining the SNAs 
(together with their associated variant allele frequencies) and informative CNAs 
(asymmetric copy number gains/amplifications or cnLOH) that were observed in all biopsies 
of a given tumour. Using an assumption of constant SNA mutation rate over time, we sought 
to time individual clonal CNAs along the history of the ancestral cell lineage, by partitioning 
the SNAs present in the same region of the CNA into those accumulated before and after the 
CNA.
The premise of the timing model is to use the information from all CNAs under 
consideration in a joint likelihood maximisation of their respective timing. The individual 
timings are estimated using the assumption that the SNAs in a CNA region will accumulate 
following a Poisson process, based itself on the assumption of a given mutation rate. The 
SNVs in a given CNA region were partitioned into those on the non-amplified and amplified 
DNA strands (referred to as alpha and beta variants respectively in the supplementary note) 
using a Gaussian mixture model, implemented using the R package ‘mixtools’ and the 
‘normalmixEM’ function. Here the parameter mu (the starting cluster means) was inferred 
from the cellularity and copy state of the CNA. For example: in a biopsy with 100% tumour 
content, the expected cluster means of a trisomy region are 0.33 and 0.67, representing, the 
non-amplified and amplified chromosomes. We performed a heuristic search (using 10,000 
iterations of the normalmixEM function) to assess the confidence in the inferred cluster 
centres. Only cases where clustering was deemed successful, determined by the final means 
of the two clusters being located within one standard deviation of the expected cluster 
means, were passed forward for timing analysis. Note that ‘complex CNAs’ – those CNAs 
where there was reason to suspect multiple alterations occurred at the same locus (for 
example focal gain after an arm gain) - were excluded from the analysis.
The statistical assessment of the distribution of the CNA timings was performed by 
comparing the distribution of timings for each tumour against a uniform distribution using 
the Kolmogorov–Smirnov test. The duration of the comparative interval was set to the 
interval between the inferred initiation of the adenoma (timing of the 5q LOH event) and the 
time most recent common ancestor (MRCA). In the cases where no 5q event was detected, 
the time of initiation of adenoma growth was taken as the average time of 5q LOH in the two 
cases where this event could be timed (adenoma 4 and carcinoma 5).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Mutation burdens in CRAs and CRCs
a. CRAs tended to have slightly fewer exonic SNAs than CRCs but the difference was not 
significant. The average burden and 95% range across these different tumours is shown by 
the rightmost bars. b. The number of individual CNAs (as measured by the number of 
segmentations) is significantly greater in CRCs than CRAs (p=0.003, 95% range shown by 
bars). c. SNA driver mutation burdens and allelic loss of 5q, 17p and 18q, are shown for 
each tumour. A comparison of all events is show by the red bars, while tier 1 driver changes 
exclusively are shown in dark grey, with tier 2 in light grey. d. Distribution of canonical 
driver mutations across tumours. APC is the only ubiquitous driver event. There is no 
significant enrichment of cnLOH mutations as second hits to APC or TP53 mutations in 
adenomas compared to carcinomas (though TP53 is borderline).
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Figure 2. Phylogenetic analysis of CRAs and MSS CRCs
Maximum parsimony construction of evolutionary trees. For tumours with only two regional 
biopsies, truncal mutations were simply those shared between the regions. Tier 1 driver 
mutations (Table S3) are shown, illustrating their enrichment on the trunks, especially in 
CRCs, indicating they are acquired early in evolutionary time. Phylogenetic trees showed 
were produced using all available SNAs. Tree shape robustness (branch support) was 
confirmed by bootstrapping. Branches had greater than 95% support unless otherwise stated 
(44/55 (80%) of branches had >95% support). The most parsimonious trees are shown 
except in carcinoma 6, where one clade could not be resolved (A: green box). Left Bar 
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chart: Ubiquitous SNAs (found in all regional biopsies and on the trunk of the phylogenetic 
tree) are compared with sub-clonal SNAs on the phylogenetic tree branches (non-ubiquitous, 
but present in >1 region) and leaf (present in only one region). CRAs have a smaller 
proportion of ubiquitous variants than CRCs.
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Figure 3. Copy number alterations in CRAs and MSS CRCs
a. A genome-wide view of CNAs is shown for each region of CRAs (top) and CRCs 
(bottom). Cancers show a greater CNA burden than adenomas, and most CNAs are clonal in 
cancers, whereas CRAs show more frequent sub-clonal CNAs. Copy number ≥5 is shown as 
“polysomy”. b. The figure shows estimated ploidy and summarises the proportion of each 
tumour at different copy-states. Black bars show the range of biopsy copy-numbers. c. Size 
distributions of ubiquitous and sub-clonal (branch and leaf) CNAs demonstrate the 
preference of CRCs to have larger events. Boxplots show the median and inter quantile 
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range (IQR), upper whisker is 3rd quantile + 1.5*IQR and lower whisker is 1st quantile - 
1.5*IQR. The colour-coding of copy number states (top right) applies to all panels.
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Figure 4. Geography of CRCs
Photographs of the tumour specimens from histopathology departments are shown, with 
biopsy locations marked. The sporadic MSI+ cancer 4 is included here. The corresponding 
phylogenetic relationship between tumour regions is shown below the photograph of each 
tumour. The regression plots show pairwise physical and genetic separation for each biopsy 
from that cancer. There was a significant positive correlation between the phylogenetic 
(mutational) distance and physical distance in every case.
Cross et al. Page 26
Nat Ecol Evol. Author manuscript; available in PMC 2019 February 28.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Figure 5. CNA timing
The plots show the CNA timing results for the six neoplasms with WGS data. For each 
tumour, the X-axis represents inferred evolutionary time to the MRCA, since tumour 
initiation (unit of measurement is SNAs accrued per unit time). Green dashed line is inferred 
from the “second hit” at APC (and thus likely represents the time of initiation of the 
adenoma). The upper panels show the accumulation of CNAs (red, arrowed line) relative to a 
steady accumulation (black, dashed line); p-values are derived from Kolmogorov-Smirnov 
tests of inferred CNA time versus a uniform accumulation. The lower panel shows the 
estimated times of driver mutations, where these could be derived, for individual CNAs by 
chromosome arm and type of change. Bars indicate 95% confidence intervals for CNA 
timing estimates.
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